QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,066 signal articles · 543 in last 24h · 103,602 total before filter · latest 9m ago
543last 24h
2521last 7d
483● bullish (7d)
259● bearish (7d)
197publishers
AllMacro247Earnings1481M&A141Regulatory16Product4Analyst30
✕ clear all filtersticker: AMGNSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Jobs Numbers, SpaceX Earnings: What to Watch This Week
The Wall Street Journal2d agoneutral
Jobs Numbers, SpaceX Earnings: What to Watch This Week

The monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.

Colorado Enbrel Price Cap Setback Might Change The Case For Investing In Amgen (AMGN)
Simply Wall St.13d agoneutral
Colorado Enbrel Price Cap Setback Might Change The Case For Investing In Amgen (AMGN)

Earlier in July, a federal judge blocked Colorado’s plan to impose a 70% price cap on Amgen’s blockbuster arthritis drug Enbrel, halting a significant state-level pricing move. The ruling eased concerns that aggressive state pricing limits on Enbrel could spread more widely, reducing a key regulatory overhang for Amgen’s portfolio. We’ll now explore how this legal setback to Colorado’s price cap effort could influence Amgen’s investment narrative and perceived long-term risks. Find 47...

Did Enbrel’s Price Cap Reprieve and New Recalls Just Rebalance Amgen’s (AMGN) Risk‑Reward Profile?
Simply Wall St.28d agobearish
Did Enbrel’s Price Cap Reprieve and New Recalls Just Rebalance Amgen’s (AMGN) Risk‑Reward Profile?

In early June 2026, a federal judge granted Amgen a preliminary injunction blocking Colorado’s proposed 70% price cap on its rheumatoid arthritis drug Enbrel, while the company also initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the United States over foreign substances and CGMP deviations. This mix of regulatory relief on Enbrel’s pricing and ongoing quality-related recalls raises important questions about how investors weigh pricing power against...

Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel
Reuters34d agoneutral
Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel

July 1 (Reuters) - A federal judge on Wednesday blocked Colorado from capping the price of Amgen's blockbuster arthritis drug Enbrel, a first-of-its-kind move ‌by a U. In granting a preliminary injunction, Chief Judge Daniel Domenico ‌of the Denver federal court said Amgen would likely face significant and irreparable harm from charging lower prices, ​adding that it could affect the drugmaker's negotiations for future contracts with wholesalers and distributors.